Type of Preadmission Glucose-lowering Treatment and Prognosis Among Patients Hospitalised with Myocardial Infarction: a Nationwide Follow-up Study

Overview

Journal Diabetologia

Specialty Endocrinology

Date 2008 Feb 20

PMID 18283428

Citations 8

Authors

H T Horsdal

S P Johnsen

F Sondergaard

J Rungby

Affiliations

Soon will be listed here.

Abstract

Aims/hypothesis: We examined whether the type of preadmission glucose-lowering treatments explained differences in mortality rate and risk of readmission with myocardial infarction (MI) and heart failure following first-time hospitalisation for MI in patients with type 2 diabetes mellitus.

Methods: We conducted a nationwide population-based follow-up study among all Danish patients hospitalised with first-time MI from 1996 to 2004. Data on use of glucose-lowering drugs and other medications, comorbidities, socioeconomic status, laboratory findings, readmission with MI and heart failure, and death were obtained from medical databases. We computed mortality rates and rates of MI and heart failure readmission, according to type of glucose-lowering treatment and used Cox's proportional hazards regression analysis to compute hazard ratios (HRs) as estimates of relative risks.

Results: We identified 8,494 MI patients with type 2 diabetes mellitus. The overall cumulative 30 day and 1 year mortality rates were 22.2 and 36.6%, respectively. Patients not receiving any glucose-lowering drugs (adjusted 30 day HR: 0.79, 95% CI: 0.57-1.10) and users of any combination (adjusted 30 day HR: 1.43, 95% CI: 0.98-2.09) had the lowest and highest mortality rates, respectively, when compared with users of sulfonylureas. We found that glycaemic control had no impact on the risk estimates in a subanalysis including biochemical laboratory data. We found no differences in the risk of new MI and heart failure between the different glucose-lowering agents.

Conclusions/interpretation: Type of preadmission glucose-lowering treatment in monotherapy is not associated with substantial differences in prognosis following hospitalisation with MI. However, patients treated with any combination had increased mortality rates.

Citing Articles

Association of Metformin with the Mortality and Incidence of Cardiovascular Events in Patients with Pre-existing Cardiovascular Diseases.

Li T, Providencia R, Jiang W, Liu M, Yu L, Gu C Drugs. 2022; 82(3):311-322.

PMID: 35032305 DOI: 10.1007/s40265-021-01665-0.

Real-world use of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: A Danish nationwide cohort study, 2012 to 2019.

Funck K, Knudsen J, Hansen T, Thomsen R, Grove E Diabetes Obes Metab. 2020; 23(2):520-529.

PMID: 33140907 PMC: 7839758. DOI: 10.1111/dom.14245.

Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study.

Knudsen J, Baggesen L, Lajer M, Nurkanovic L, Ustyugova A, Sorensen H PLoS One. 2020; 15(3):e0229621.

PMID: 32130249 PMC: 7055862. DOI: 10.1371/journal.pone.0229621.

Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies.

Pladevall M, Riera-Guardia N, Margulis A, Varas-Lorenzo C, Calingaert B, Perez-Gutthann S BMC Cardiovasc Disord. 2016; 16:14.

PMID: 26769243 PMC: 4714432. DOI: 10.1186/s12872-016-0187-5.

The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies.

Varas-Lorenzo C, Margulis A, Pladevall M, Riera-Guardia N, Calingaert B, Hazell L BMC Cardiovasc Disord. 2014; 14:129.

PMID: 25260374 PMC: 4246471. DOI: 10.1186/1471-2261-14-129.

References

Turner R, Cull C, Frighi V, Holman R . Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999; 281(21):2005-12. DOI: 10.1001/jama.281.21.2005. View

McAfee A, Koro C, Landon J, Ziyadeh N, Walker A . Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Saf. 2007; 16(7):711-25. DOI: 10.1002/pds.1443. View

Halkin A, Roth A, Jonas M, Behar S . Sulfonylureas are not associated with increased mortality in diabetics treated with thrombolysis for acute myocardial infarction. J Thromb Thrombolysis. 2001; 12(2):177-84. DOI: 10.1023/a:1012979622945. View

. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):854-65. View

Nielsen G, Sorensen H, Pedersen A, Sabroe S . Analyses of data quality in registries concerning diabetes mellitus--a comparison between a population based hospital discharge and an insulin prescription registry. J Med Syst. 1996; 20(1):1-10. DOI: 10.1007/BF02260869. View

Sauer W, Cappola A, Berlin J, Kimmel S . Insulin sensitizing pharmacotherapy for prevention of myocardial infarction in patients with diabetes mellitus. Am J Cardiol. 2006; 97(5):651-4. DOI: 10.1016/j.amjcard.2005.09.106. View

Gustafsson I, Hildebrandt P, Seibaek M, Melchior T, Torp-Pedersen C, Kober L . Long-term prognosis of diabetic patients with myocardial infarction: relation to antidiabetic treatment regimen. The TRACE Study Group. Eur Heart J. 2000; 21(23):1937-43. DOI: 10.1053/euhj.2000.2244. View

Johnsen S, Monster T, Olsen M, Thisted H, McLaughlin J, Sorensen H . Risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs. Am J Ther. 2006; 13(2):134-40. DOI: 10.1097/00045391-200603000-00009. View

Lachin J, Christophi C, Edelstein S, Ehrmann D, Hamman R, Kahn S . Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program. Diabetes. 2007; 56(4):1153-9. PMC: 2533728. DOI: 10.2337/db06-0918. View

10.

Garratt K, Brady P, Hassinger N, Grill D, Terzic A, Holmes Jr D . Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol. 1999; 33(1):119-24. DOI: 10.1016/s0735-1097(98)00557-9. View

11.

FRANK L . Epidemiology. When an entire country is a cohort. Science. 2000; 287(5462):2398-9. DOI: 10.1126/science.287.5462.2398. View

12.

Madsen M, Balling H, Eriksen L . [The validity of the diagnosis of acute myocardial infarction in 2 registries: the Heart Registry compared to the National Patient Registry]. Ugeskr Laeger. 1990; 152(5):308-14. View

13.

Fisman E, Tenenbaum A, Benderly M, Goldbourt U, Behar S, Motro M . Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up. Cardiology. 1999; 91(3):195-202. DOI: 10.1159/000006909. View

14.

Kao J, Tobis J, McClelland R, Heaton M, Davis B, Holmes Jr D . Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. Am J Cardiol. 2004; 93(11):1347-50, A5. DOI: 10.1016/j.amjcard.2004.02.028. View

15.

Steen H, Giannitsis E, Futterer S, Merten C, Juenger C, Katus H . Cardiac troponin T at 96 hours after acute myocardial infarction correlates with infarct size and cardiac function. J Am Coll Cardiol. 2006; 48(11):2192-4. DOI: 10.1016/j.jacc.2006.06.002. View

16.

Murcia A, Hennekens C, Lamas G, Jimenez-Navarro M, Rouleau J, Flaker G . Impact of diabetes on mortality in patients with myocardial infarction and left ventricular dysfunction. Arch Intern Med. 2004; 164(20):2273-9. DOI: 10.1001/archinte.164.20.2273. View

17.

Andersen T, Madsen M, Jorgensen J, Mellemkjoer L, Olsen J . The Danish National Hospital Register. A valuable source of data for modern health sciences. Dan Med Bull. 1999; 46(3):263-8. View

18.

Meier J, Deifuss S, Klamann A, Schmiegel W, Nauck M . Influence of an antidiabetic treatment with sulfonylurea drugs on long-term survival after acute myocardial infarction in patients with type 2 diabetes. The LAngendreer Myocardial infarction and Blood glucose in Diabetic patients Assessment (LAMBDA). Exp Clin Endocrinol Diabetes. 2003; 111(6):344-50. DOI: 10.1055/s-2003-42725. View

19.

Malmberg K, Yusuf S, Gerstein H, Brown J, Zhao F, Hunt D . Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation. 2000; 102(9):1014-9. DOI: 10.1161/01.cir.102.9.1014. View

20.

McGuire D, Newby L, Bhapkar M, Moliterno D, Hochman J, Klein W . Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. Am Heart J. 2004; 147(2):246-52. DOI: 10.1016/j.ahj.2003.07.024. View